Optimal management of retinal vein occlusion (RVO) is still a matter of debate. The purpose of this pilot study was to investigate whether nadroparin calcium may play some role in the treatment of recent onset (≤3 weeks' duration) RVO.
Methods:
Twenty-four RVO patients were treated with subcutaneous nadroparin calcium (200 I.U./kg/day) for 6 weeks. Best corrected visual acuity (BCVA) and macular thickness in the affected eye were measured at baseline, and after 3 and 6 months. Twenty-four RVO patients treated with oral pentoxifylline, matched for age, gender, RVO type, eye involvement, and BCVA at presentation, randomly selected from the RVO register, were used as controls.
Results:
Median BCVAs at baseline, month 3, and month 6 were 20/70 (range: 20/1,000–20/20), 20/40 (range: 20/100–20/20), and 20/30 (range: 20/200–20/20) in cases and 20/70 (range: 20/1,000–20/20), 20/60 (range: 20/320–20/25), and 20/60 (range: 20/500–20/20) in controls. Differences between groups were statistically significant at months 3 (P=0.025) and 6 (P=0.024). In the study group, the mean macular thickness was 510±207 μm at baseline, 384±198 μm after 3 months, and 313±170 μm after 6 months. Differences between baseline and months 3 and 6 were statistically significant (P=0.004 and P<0.001).
Conclusions:
Results suggest that nadroparin calcium might become a potential candidate for the treatment of RVO. Larger trials are necessary to confirm these preliminary findings.
KleinR., MossS.E., MeuerS.M., KleinB.E.The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch. Ophthalmol., 126:513–518. 2008.
4.
MohamedQ., McIntoshR.L., SawS.M., WongT.Y.Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology., 114:507–519. 2007.
5.
McIntoshR.L., MohamedQ., SawS.M., WongT.Y.Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology., 114:835–854. 2007.
6.
BadalaF.The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin. Ophthalmol., 19:234–238. 2008.
7.
CampochiaroP.A., HeierJ.S., FeinerL.et al.Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology., 117:1102–1112.e1. 2010.
8.
BrownD.M., CampochiaroP.A., SinghR.P.et al.Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology., 117:1124–1133.e1. 2010.
9.
BrownD.M., CampochiaroP.A., BhisitkulR.B.et al.Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology., 118:1594–1602. 2011.
10.
CampochiaroP.A., BrownD.M., AwhC.C.et al.Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology., 118:2041–2049. 2011.
11.
HeierJ.S., CampochiaroP.A., YauL.et al.Ranibizumab for macular edema due to retinal vein occlusions long-term follow-up in the HORIZON trial. Ophthalmology., 119:802–809. 2012.
HallerJ.A., BandelloF., BelfortR.Jr.et al.Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology., 117:1134–1146.e3. 2010.
14.
HallerJ.A., BandelloF., BelfortR.et al.Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology., 118:2453–2460. 2011.
RomanowskaB., GoszczA., GrodzińskaL., BierońK., Kostka-TrabkaE.Evaluation of fraxiparine efficacy in the treatment of retinal vein occlusion. Klin. Oczna., 101:451–454. 1999.
17.
FarahvashM.S., MoghaddamM.M., MoghimiS., MohammadzadehS.Dalteparin in the management of recent onset central retinal vein occlusion: a comparison with acetylsalicylic acid. Can. J. Ophthalmol., 43:79–83. 2008.
18.
AgenoW., CattaneoR., ManfrediE.et al.Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study. Thromb. Res., 125:137–141. 2010.
19.
SquizzatoA., ManfrediE., BozzatoS., DentaliF., AgenoW.Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action. Thromb. Haemost., 103:271–276. 2010.
20.
Lazo-LangnerA., HawelJ., AgenoW., KovacsM.J.Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials. Haematologica., 95:1587–1593. 2010.
21.
PrandoniP., CarnovaliM., MarchioriA.et al.Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch. Intern. Med., 164:1077–1083. 2004.
22.
WardA., ClissoldS.P.Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs., 34:50–97. 1987.
23.
De SanctisM.T., CesaroneM.R., BelcaroG.et al.Treatment of retinal vein thrombosis with pentoxifylline: a controlled, randomized trial. Angiology., 53:S35–S38. 2002.
24.
MitchellP., SmithW., ChangA.Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye Study. Arch. Ophthalmol., 114:1243–1247. 1996.
25.
KleinR., KleinB.E., MossS.E., MeuerS.M.The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans. Am. Ophthalmol. Soc., 98:133–141. 2000.
26.
The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch. Ophthalmol., 114:545–554. 1996.
27.
HayrehS.S.Management of central retinal vein occlusion. Ophthalmologica., 217:167–288. 2003.
28.
FekratS., FinkelsteinD.Current concepts in the management of central retinal vein occlusion. Curr. Opin. Ophthalmol., 8:50–54. 1997.
MruthyunjayaP., WirostkoW.J., ChandrashekharR.et al.Central retinal vein occlusion in patients treated with long-term warfarin sodium (Coumadin) for anticoagulation. Retina., 26:285–291. 2006.
31.
KohnerE.M., PettiJ.E., HamiltonA.M., BulpittC.J., DolleryC.T.Streptokinase in central vein occlusion: a controlled clinical trial. Br. Med. J., 1:550–553. 1976.
32.
HoutsmullerA.J., VermeulenJ.A., KlompeM.et al.The influence of ticlopidine on the natural course of retinal vein occlusion. Agents Actions Suppl., 15:219–29. 1984.
33.
ElmanM.J.Thrombolytic therapy for central retinal vein occlusion: results of a pilot study. Trans. Am. Ophthalmol. Soc., 94:471–504. 1996.
34.
The Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: N report. Ophthalmology., 102:1434–1444. 1995.
35.
KumarB., YuD., MorganW.H., BarryC.J., ConstableI.J., McAllisterI.L.The distribution of angioarchitectural changes within the vicinity of the arteriovenous crossing in branch retinal vein occlusion. Ophthalmology., 105:424–427. 1998.
36.
The Eye Disease Case-Control Study Group. Risk factors for branch retinal vein occlusion. Am. J. Ophthalmol., 116:286–296. 1993.
37.
LipP.L., BlannA.D., JonesA.F., LipG.Y.Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. Eye., 12:45–51. 1998.
38.
BearellyS., FekratS.Controversy in the management of retinal venous occlusive disease. Int. Ophthalmol. Clin., 44:85–102. 2004.
39.
WuL., ArevaloJ.F., BerrocalM.H.et al.Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months. Retina., 29:1396–1403. 2009.
40.
JullA., WatersJ., ArrolB.Pentoxifylline for treatment of venous leg ulcers: a systematic review. Lancet., 2002; 359:1550–1554.
41.
ParkC.H., ScottA.W., FekratS.Effect of oral pentoxifylline on cystoid macular edema associated with central retinal vein occlusion. Retina., 27:1020–1025. 2007.
42.
FerroniP., FormicaV., RoselliM., GuadagniF.Thromboembolic events in patients treated with anti-angiogenic drugs. Curr. Vasc. Pharmacol., 8:102–113. 2010.
